Oligonucleotides

With the global market size predicted to reach USD 1489.5 million by 2024, the additional capacity requirements for molecular-target agents employing chemically synthesized oligonucleotides (Oligos) will be significant. DPS has been designing and implementing manufacturing facilities for oligonucleotides and peptides for clients over many years and our teams have a great understanding of the synthetic chemistry and purification processes, coupled with the expertise around aseptic drug product formulation and filling process design. We understand the ‘merging’ of both small-molecule and large-molecule biologic manufacturing process unit operations and developing design solutions for the particular complexities around handling and disposal of large volume solvents. 

Our teams are at the forefront of these designs and can guide you in the design of facilities for scale-up and commercialization of your synthetic oligonucleotide candidates, be they anti-sense oligonucleotides, short interfering RNA (siRNA) and microRNA (miRNA), aptamers or CpG oligos. Our regulatory consultants are also available to provide guidance in navigating the regulatory aspects of facility design and licensure. Call our team to discuss how we can assist you in evolving your plans.

Back to top
DPS Group addresses the COVID-19 pandemic:
A message from Frank Keogh, CEO

Find out more Contact Us